Evidence map›Paper›PMID 41279620›Full record

ArticlebioRxiv : the preprint server for biology2025

Engineering HIV antibodies with enhanced breadth and potency of neutralization through multistate affinity maturation.

Mateusz Kędzior, Swastik Phulera, Monica L Fernández-Quintero, Johannes R Loeffler, Collin Joyce, Jordan Woehl, Abdolrahim Abbasi, Maryam Karimi, Arash Aslanabadi, Mahsa Hojabri and 21 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Mateusz KędziorNeutralizing Antibody Center, IAVI, San Diego, CA, USA.ORCID 0000-0002-9250-9925
Swastik PhuleraDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, USA.
Monica L Fernández-QuinteroDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, USA.
Johannes R LoefflerDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, USA.
Collin JoyceDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Jordan WoehlDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Abdolrahim AbbasiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Maryam KarimiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Arash AslanabadiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Mahsa HojabriInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Roza ZareidoodejiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Ben AtkinsonInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Eduar Fernando Pinzon BurgosInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Alonso HerediaInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Karen Saye-FranciscoDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Quoc TranDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Yoojin KimDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Fernando Acosta-PuenteDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Lara ShahinNeutralizing Antibody Center, IAVI, San Diego, CA, USA.
Amelia ZhouNeutralizing Antibody Center, IAVI, San Diego, CA, USA.
Pilar X AltmanNeutralizing Antibody Center, IAVI, San Diego, CA, USA.ORCID 0000-0002-2909-0666
Nathaniel R FelbingerInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA.
Brian G PierceInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA.
Devin SokNeutralizing Antibody Center, IAVI, San Diego, CA, USA.
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Dennis R BurtonDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.
Anthony L DeVicoInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, USA.ORCID 0000-0001-7153-3769
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, Scripps Research, La Jolla, CA, USA.
Mohammad M SajadiInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-7798-3605
Joseph G JardineDepartment of Immunology and Microbiology, Scripps Research, La Jolla, CA, USA.

Funding

Novel bNAB-based treatment and prevention of HIV-1R01AI155150 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2021 to 2024
$2.8M
Engineering of pan-neutralizing anti-HIV envelope antibodiesR01AI147870 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SAJADI, MOHAMMAD MOHSENI · 2020 to 2024
$2.5M
Gates Foundation INV-005284Gates Foundation INV-036842NIAID NIH HHS R01 AI147870NIAID NIH HHS R01 AI155150
6 · The paper itself

Abstract

Broadly neutralizing antibodies (bnAbs) against HIV hold promise as therapeutic and prophylactic agents, but realizing this potential requires antibodies that function across the antigenic heterogeneity of the HIV envelope glycoprotein (Env). Although numerous bnAbs have been isolated from infected individuals, their breadth and potency may not be sufficient to tackle global viral diversity, motivating efforts to further improve their neutralization capacity. Here, we address this challenge using a multistate antibody engineering approach integrating deep mutational scanning with combinatorial library screening across diverse Env variants. This strategy enables identification of mutation patterns that confer improved binding across antigenically distinct targets. Starting from one of the best-in-class CD4-binding site bnAbs, we performed iterative optimization to increase binding affinity across diverse Env variants. The resulting lead candidate exhibited improved breadth and up to 100-fold higher potency against pseudoviruses from large cross-clade historical and contemporary panels while maintaining biophysical and pharmacokinetic profiles conducive to clinical development. Structural and molecular dynamics analyses revealed a unique tri-tyrosine aromatic triad and reinforced electrostatic contacts that stabilized the bnAb/Env interface. These findings demonstrate that systematic

Identifiers

PMID41279620
PMCPMC12633424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.